160 related articles for article (PubMed ID: 31053527)
1. Immunohistochemical expression of CD44, matrix metalloproteinase2 and matrix metalloproteinase9 in renal cell carcinomas.
Lee YM; Kim JM; Lee HJ; Seong IO; Kim KH
Urol Oncol; 2019 Oct; 37(10):742-748. PubMed ID: 31053527
[TBL] [Abstract][Full Text] [Related]
2. pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma.
Struckmann K; Mertz K; Steu S; Storz M; Staller P; Krek W; Schraml P; Moch H
J Pathol; 2008 Mar; 214(4):464-71. PubMed ID: 18189328
[TBL] [Abstract][Full Text] [Related]
3. Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC.
Ma J; Li M; Chai J; Wang K; Li P; Liu Y; Zhao D; Xu J; Yu K; Yan Q; Guo S; Wang Z; Fan L
Diagn Pathol; 2020 Mar; 15(1):28. PubMed ID: 32209138
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
5. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas.
Mikami S; Mizuno R; Kosaka T; Saya H; Oya M; Okada Y
Int J Cancer; 2015 Apr; 136(7):1504-14. PubMed ID: 25123505
[TBL] [Abstract][Full Text] [Related]
6. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma.
Bhuvarahamurthy V; Kristiansen GO; Johannsen M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2006 May; 15(5):1379-84. PubMed ID: 16596214
[TBL] [Abstract][Full Text] [Related]
7. G6PD upregulates Cyclin E1 and MMP9 to promote clear cell renal cell carcinoma progression.
Zhang Q; Ni Y; Wang S; Agbana YL; Han Q; Liu W; Bai H; Yi Z; Yi X; Zhu Y; Sai B; Yang L; Shi Q; Kuang Y; Yang Z; Zhu Y
Int J Med Sci; 2022; 19(1):47-64. PubMed ID: 34975298
[No Abstract] [Full Text] [Related]
8. Expression of Snail and Slug in renal cell carcinoma: E-cadherin repressor Snail is associated with cancer invasion and prognosis.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mukai M; Okada Y
Lab Invest; 2011 Oct; 91(10):1443-58. PubMed ID: 21808237
[TBL] [Abstract][Full Text] [Related]
9. Does the Immunohistochemical Expression of CD44, MMP-2, and MMP-9 in Association with the Histopathological Subtype of Renal Cell Carcinoma Affect the Survival of Patients with Renal Cancer?
Chrabańska M; Rynkiewicz M; Kiczmer P; Drozdzowska B
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831550
[TBL] [Abstract][Full Text] [Related]
10. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
11. miR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1/MEK/ERK/MMP2/MMP9 pathway.
Wang J; Wang C; Li Q; Guo C; Sun W; Zhao D; Jiang S; Hao L; Tian Y; Liu S; Sun MZ
Biomed Pharmacother; 2020 Jul; 127():110215. PubMed ID: 32413671
[TBL] [Abstract][Full Text] [Related]
12. Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases.
Lim SD; Young AN; Paner GP; Amin MB
Virchows Arch; 2008 Jan; 452(1):49-55. PubMed ID: 18026989
[TBL] [Abstract][Full Text] [Related]
13. Increased expression of matrix metalloproteinase 9 correlates with poor prognostic variables in renal cell carcinoma.
Cho NH; Shim HS; Rha SY; Kang SH; Hong SH; Choi YD; Hong SJ; Cho SH
Eur Urol; 2003 Nov; 44(5):560-6. PubMed ID: 14572755
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma.
Tawfik OW; Kramer B; Shideler B; Danley M; Kimler BF; Holzbeierlein J
Arch Pathol Lab Med; 2007 Feb; 131(2):261-7. PubMed ID: 17284111
[TBL] [Abstract][Full Text] [Related]
15. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma.
Zanjani LS; Madjd Z; Abolhasani M; Rasti A; Fodstad O; Andersson Y; Asgari M
Biomark Med; 2018 Jan; 12(1):45-61. PubMed ID: 29243496
[TBL] [Abstract][Full Text] [Related]
17. Identifying and validating MMP family members (MMP2, MMP9, MMP12, and MMP16) as therapeutic targets and biomarkers in kidney renal clear cell carcinoma (KIRC).
Li K; Li D; Hafez B; Bekhit MMS; Jardan YAB; Alanazi FK; Taha EI; Auda SH; Ramzan F; Jamil M
Oncol Res; 2024; 32(4):737-752. PubMed ID: 38560573
[TBL] [Abstract][Full Text] [Related]
18. RALY RNA binding protein-like reduced expression is associated with poor prognosis in clear cell renal cell carcinoma.
Cui ZW; Xia Y; Ye YW; Jiang ZM; Wang YD; Wu JT; Sun L; Zhao J; Fa PP; Sun XJ; Gui YT; Cai ZM
Asian Pac J Cancer Prev; 2012; 13(7):3403-8. PubMed ID: 22994768
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical Expression of CD44, MMP-2, MMP-9, and Ki-67 as the Prognostic Markers in Non-Clear Cell Renal Cell Carcinomas-A Prospective Cohort Study.
Chrabańska M; Rynkiewicz M; Kiczmer P; Drozdzowska B
J Clin Med; 2022 Sep; 11(17):. PubMed ID: 36079127
[TBL] [Abstract][Full Text] [Related]
20. Gelsolin inhibits the proliferation and invasion of the 786-0 clear cell renal cell carcinoma cell line in vitro.
Zhu X; Cai L; Meng Q; Jin X
Mol Med Rep; 2015 Nov; 12(5):6887-94. PubMed ID: 26398833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
